Abeona Therapeutics Inc (NASDAQ:ABEO) shares traded up 9.2% during mid-day trading on Friday . The company traded as high as $8.14 and last traded at $8.10. 657,079 shares were traded during mid-day trading, an increase of 65% from the average session volume of 399,426 shares. The stock had previously closed at $7.42.
A number of research analysts have issued reports on the company. ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, February 21st. BidaskClub downgraded Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 12th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 6th. Finally, Mizuho restated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research note on Monday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $26.88.
The company has a market capitalization of $355.74 million, a price-to-earnings ratio of -12.27 and a beta of 1.93.
TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4224632/abeona-therapeutics-abeo-trading-9-2-higher.html.
Abeona Therapeutics Company Profile (NASDAQ:ABEO)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Story: What is Put Option Volume?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.